{"id":"vancomycin-iv","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nephrotoxicity (acute kidney injury)"},{"rate":"1-5","effect":"Ototoxicity (hearing loss)"},{"rate":"10-15","effect":"Red man syndrome (flushing, pruritus, erythema)"},{"rate":"5-10","effect":"Phlebitis at infusion site"},{"rate":"5","effect":"Fever"},{"rate":"5","effect":"Chills"},{"rate":"5","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, blocking the cross-linking reactions catalyzed by transpeptidases. This prevents proper cell wall formation and integrity, leading to bacterial cell lysis and death. It is bactericidal and particularly effective against gram-positive organisms.","oneSentence":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:12.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)"},{"name":"Bacterial endocarditis"},{"name":"Clostridium difficile-associated diarrhea and colitis"},{"name":"Staphylococcal enterocolitis"},{"name":"Gram-positive infections in penicillin-allergic patients"}]},"trialDetails":[{"nctId":"NCT06748144","phase":"PHASE2, PHASE3","title":"IO Vancomycin Spine","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-05","conditions":"Lumbar Fusion Surgery","enrollment":30},{"nctId":"NCT06293352","phase":"NA","title":"Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-08-08","conditions":"Prosthetic-joint Infection, Knee Infection, Arthroplasty Complications","enrollment":153},{"nctId":"NCT06889701","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","startDate":"2025-04-03","conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33},{"nctId":"NCT06637332","phase":"PHASE4","title":"Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2024-11-14","conditions":"Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia","enrollment":300},{"nctId":"NCT03785210","phase":"PHASE2","title":"Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-05","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer","enrollment":22},{"nctId":"NCT02701608","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":"Infective Endocarditis","enrollment":162},{"nctId":"NCT02701595","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":"Infective Endocarditis","enrollment":324},{"nctId":"NCT07267013","phase":"PHASE2","title":"Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC)","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-03-30","conditions":"Aortic Surgery, Extracorporeal Circulation","enrollment":25},{"nctId":"NCT07084129","phase":"PHASE1","title":"Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2026-04","conditions":"Sepsis","enrollment":20},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":"Aspiration, Aspiration Pneumonia","enrollment":5},{"nctId":"NCT07283068","phase":"NA","title":"IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02-15","conditions":"Revision Total Knee Arthroplasty","enrollment":40},{"nctId":"NCT04729322","phase":"PHASE2","title":"Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-22","conditions":"Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8","enrollment":15},{"nctId":"NCT07282782","phase":"PHASE4","title":"A Prospective, Randomized Parallel Group Study of the Efficacy of Vancomycin Administered Through Intraarticular Injection Versus Intraosseous Injection Versus Intravenous Infusion in Patients Undergoing Total Knee Arthroplasty","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-06-10","conditions":"Total Knee Arthroplasty","enrollment":30},{"nctId":"NCT06540391","phase":"PHASE1","title":"A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Microbiotica Ltd","startDate":"2024-08-28","conditions":"Melanoma","enrollment":41},{"nctId":"NCT05831774","phase":"PHASE4","title":"IO Vancomycin in TSA","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-06-01","conditions":"Shoulder Injuries","enrollment":33},{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT04399642","phase":"NA","title":"Intra-articular Vancomycin Powder in Knee and Hip Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2019-07-05","conditions":"Infection","enrollment":1832},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07107477","phase":"PHASE3","title":"TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden","status":"RECRUITING","sponsor":"The Central and Eastern European Gynecologic Oncology Group","startDate":"2025-05-01","conditions":"Preterm Premature Rupture of Membranes (PPROM)","enrollment":138},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":100},{"nctId":"NCT07072923","phase":"PHASE4","title":"Antibiotic Impregnated Beads in Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2025-09-01","conditions":"Osteomyelitis of the Foot, Antibiotic Impregnated Beads, Osteomyelitis of Lower Extremities","enrollment":100},{"nctId":"NCT06601257","phase":"PHASE1","title":"Vancomycin Dose Optimization in Obesity","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-04-01","conditions":"Pharmacokinetics and Pharmacodynamics","enrollment":24},{"nctId":"NCT06640491","phase":"PHASE1, PHASE2","title":"Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-05-15","conditions":"Total Knee Arthroplasty","enrollment":40},{"nctId":"NCT04911270","phase":"NA","title":"Clinical Decision Support Tool for Vancomycin Dosing in Children","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2022-05-09","conditions":"Gram-Positive Bacterial Infections, Vancomycin, Pharmacokinetics","enrollment":75},{"nctId":"NCT05225558","phase":"PHASE2","title":"A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia","status":"TERMINATED","sponsor":"LigaChem Biosciences, Inc.","startDate":"2022-04-26","conditions":"MRSA Bacteremia","enrollment":40},{"nctId":"NCT03713528","phase":"PHASE4","title":"Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI?","status":"ENROLLING_BY_INVITATION","sponsor":"OrthoCarolina Research Institute, Inc.","startDate":"2020-01-14","conditions":"Joint Infection","enrollment":100},{"nctId":"NCT04042233","phase":"PHASE4","title":"Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2019-12-31","conditions":"Prosthetic Joint Infection, Vancomycin, Joint Diseases","enrollment":23},{"nctId":"NCT06384651","phase":"PHASE4","title":"Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-03","conditions":"Infections, Ankle Arthritis","enrollment":40},{"nctId":"NCT06543940","phase":"NA","title":"Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-09-01","conditions":"AKI - Acute Kidney Injury","enrollment":8},{"nctId":"NCT05849090","phase":"EARLY_PHASE1","title":"Vancomycin and Tobramycin Powder Use in Acute Open Fractures","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-03-27","conditions":"Infections","enrollment":10},{"nctId":"NCT04775953","phase":"PHASE2","title":"DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Staphylococcal Bacteraemia","enrollment":200},{"nctId":"NCT05959603","phase":"PHASE3","title":"Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery","status":"RECRUITING","sponsor":"Rabin Medical Center","startDate":"2020-05-31","conditions":"Infection","enrollment":363},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT02254967","phase":"PHASE4","title":"A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-11-06","conditions":"Clostridium Difficile","enrollment":364},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":"Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections","enrollment":199},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":"Staphylococcus Aureus Bacteremia","enrollment":290},{"nctId":"NCT03817125","phase":"PHASE1","title":"Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention","status":"COMPLETED","sponsor":"Parker Institute for Cancer Immunotherapy","startDate":"2019-01-28","conditions":"Metastatic Melanoma","enrollment":14},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT06084754","phase":"NA","title":"Effect of Pulsed Electromagnetic Field Stimulation on Localized Pediatric Osteomyelitis","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-11-27","conditions":"Osteomyelitis","enrollment":20},{"nctId":"NCT00501150","phase":"NA","title":"Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2005-09","conditions":"Gram-positive Bacterial Infections, Staphylococcal Infections","enrollment":211},{"nctId":"NCT03182907","phase":"PHASE3","title":"Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-03-27","conditions":"Clostridium Difficile Infection","enrollment":148},{"nctId":"NCT03439124","phase":"PHASE3","title":"Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2017-11-27","conditions":"Community-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)","enrollment":138},{"nctId":"NCT03137173","phase":"PHASE3","title":"Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2018-02-19","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":679},{"nctId":"NCT01734694","phase":"PHASE4","title":"Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2011-10","conditions":"Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis","enrollment":100},{"nctId":"NCT00324922","phase":"PHASE3","title":"Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-05-01","conditions":"Osteomyelitis, Methicillin-resistant Staphylococcus Aureus","enrollment":2},{"nctId":"NCT04317963","phase":"","title":"Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2020-02-12","conditions":"Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence","enrollment":180},{"nctId":"NCT05705843","phase":"PHASE4","title":"IO vs IV Vancomycin in Tourniquetless TKA","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-25","conditions":"Infection, Surgical Site","enrollment":40},{"nctId":"NCT04673877","phase":"PHASE1","title":"Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-08-26","conditions":"Infection, Hand Injury Wrist, Hand Injuries","enrollment":20},{"nctId":"NCT01252719","phase":"PHASE3","title":"Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2010-12","conditions":"Wound Infection, Abscess, Systemic Inflammation","enrollment":968},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT04042077","phase":"PHASE3","title":"Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections","status":"TERMINATED","sponsor":"Menarini Group","startDate":"2019-09-25","conditions":"Surgical Site Infection","enrollment":268},{"nctId":"NCT01252732","phase":"PHASE3","title":"Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2010-12","conditions":"Wound Infection, Abscess, Systemic Inflammation","enrollment":1019},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02631408","phase":"PHASE4","title":"Intrawound Vancomycin Powder in Spinal Fusion Surgery","status":"COMPLETED","sponsor":"Orthopedic Hospital Vienna Speising","startDate":"2015-08","conditions":"Spinal Fusion Acquired","enrollment":308},{"nctId":"NCT00442832","phase":"PHASE2","title":"TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2006-12","conditions":"Staphylococcal Skin Infection","enrollment":203},{"nctId":"NCT03221023","phase":"PHASE2, PHASE3","title":"Intrawound Vancomycin Prophylaxis for Neural Stimulator","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2017-09-15","conditions":"Vancomycin, Implantable Neural Stimulator, Deep Brain Stimulation","enrollment":900},{"nctId":"NCT03051698","phase":"PHASE4","title":"C1-inhibitor in Allergic ASThma Patients","status":"TERMINATED","sponsor":"T. van der Poll","startDate":"2016-11-16","conditions":"Asthma","enrollment":37},{"nctId":"NCT02814318","phase":"","title":"Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization","status":"TERMINATED","sponsor":"TriHealth Inc.","startDate":"2016-06","conditions":"Group B Streptococcal Infection","enrollment":41},{"nctId":"NCT02764359","phase":"NA","title":"Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens","status":"UNKNOWN","sponsor":"CAMC Health System","startDate":"2016-08-01","conditions":"Infection, Sepsis, Obesity","enrollment":128},{"nctId":"NCT04241744","phase":"PHASE4","title":"Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI","status":"WITHDRAWN","sponsor":"Creighton University","startDate":"2019-10-29","conditions":"CDI","enrollment":""},{"nctId":"NCT03506347","phase":"PHASE2, PHASE3","title":"Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-09-24","conditions":"Arthropathy of Knee Joint","enrollment":24},{"nctId":"NCT01775397","phase":"PHASE4","title":"A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System","status":"TERMINATED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-11-29","conditions":"Clostridium Difficile","enrollment":12},{"nctId":"NCT02426918","phase":"PHASE2","title":"Study of Debio 1450 for Bacterial Skin Infections","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2015-05","conditions":"Bacterial Infections","enrollment":330},{"nctId":"NCT01283581","phase":"PHASE2","title":"A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2011-01","conditions":"Skin and Subcutaneous Tissue Bacterial Infections","enrollment":256},{"nctId":"NCT02057198","phase":"PHASE4","title":"Impact of Oral Antibiotic Treatment on C. Difficile","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-06-10","conditions":"C. Difficile, Diarrhea, Enterocolitis","enrollment":33},{"nctId":"NCT02384200","phase":"PHASE4","title":"A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2015-03","conditions":"Nephrolithiasis, Urinary Tract Infections","enrollment":86},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial","enrollment":120},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT00091819","phase":"PHASE3","title":"Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2005-01","conditions":"Staphylococcal Skin Infection","enrollment":862},{"nctId":"NCT00124020","phase":"PHASE3","title":"Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2005-01","conditions":"Bacterial Pneumonia","enrollment":771},{"nctId":"NCT00107978","phase":"PHASE3","title":"Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2005-02","conditions":"Staphylococcal Skin Infection","enrollment":1035},{"nctId":"NCT00062647","phase":"PHASE2","title":"Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2003-08","conditions":"Gram-Positive Bacterial Infections","enrollment":60},{"nctId":"NCT00077675","phase":"PHASE2","title":"Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2004-02","conditions":"Infections, Gram-positive Bacterial","enrollment":201},{"nctId":"NCT00107952","phase":"PHASE3","title":"Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2005-02","conditions":"Bacterial Pneumonia","enrollment":761},{"nctId":"NCT00061633","phase":"PHASE2","title":"Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2003-06","conditions":"Infections, Gram-Positive Bacterial, Abscess, Burns","enrollment":169},{"nctId":"NCT01175707","phase":"PHASE4","title":"Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-07-15","conditions":"Complicated Skin or Skin Structure Infection","enrollment":80},{"nctId":"NCT00695903","phase":"PHASE2","title":"Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-09-17","conditions":"Endocarditis, Bacterial, Infective Endocarditis","enrollment":38},{"nctId":"NCT01241552","phase":"PHASE3","title":"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-10","conditions":"Clostridium Difficile Infection","enrollment":1452},{"nctId":"NCT01104662","phase":"PHASE4","title":"Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-04-19","conditions":"Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment","enrollment":92},{"nctId":"NCT01513239","phase":"PHASE3","title":"A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-01","conditions":"Clostridium Difficile Infection","enrollment":1203},{"nctId":"NCT01419184","phase":"PHASE4","title":"Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-09-09","conditions":"Staphylococcal Skin Infections","enrollment":250},{"nctId":"NCT00711802","phase":"PHASE4","title":"Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-07-23","conditions":"Skin Diseases, Infectious","enrollment":396},{"nctId":"NCT01728376","phase":"PHASE4","title":"Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-11-29","conditions":"Bacteremia","enrollment":82},{"nctId":"NCT01922011","phase":"PHASE3","title":"Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2013-09-13","conditions":"Acute Hematogenous Osteomyelitis","enrollment":149},{"nctId":"NCT02466698","phase":"PHASE2, PHASE3","title":"Intestinal Lavage for the Treatment of Severe C. Difficile Infections","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2016-08","conditions":"Clostridium Difficile","enrollment":20},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":"Osteomyelitis","enrollment":30},{"nctId":"NCT01401023","phase":"NA","title":"Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Gary E. Stein, Pharm.D.","startDate":"2011-07","conditions":"Diarrhea, Clostridium Difficile","enrollment":10},{"nctId":"NCT01764750","phase":"PHASE1","title":"Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-01","conditions":"Surgical Site Infection","enrollment":10},{"nctId":"NCT00871104","phase":"PHASE4","title":"Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2009-07","conditions":"Infective Endocarditis","enrollment":50},{"nctId":"NCT02926846","phase":"PHASE4","title":"IV Antibiotics With Lavage for Severe PD Peritonitis","status":"COMPLETED","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2014-03","conditions":"Peritonitis, Kidney Failure","enrollment":46},{"nctId":"NCT00428844","phase":"PHASE2","title":"Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2007-06-26","conditions":"Osteomyelitis","enrollment":75},{"nctId":"NCT01984684","phase":"PHASE3","title":"Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2014-05","conditions":"Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections","enrollment":850},{"nctId":"NCT01570192","phase":"PHASE2","title":"Clinical Trials to Reduce the Risk of Antimicrobial Resistance","status":"TERMINATED","sponsor":"University of Florida","startDate":"2010-09","conditions":"Bacterial Pneumonia","enrollment":43},{"nctId":"NCT01811732","phase":"PHASE3","title":"Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2013-04","conditions":"Skin and Subcutaneous Tissue Bacterial Infections","enrollment":660},{"nctId":"NCT02202135","phase":"PHASE3","title":"Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2014-06","conditions":"Complicated Skin and Soft Tissue Infection","enrollment":4},{"nctId":"NCT01499277","phase":"PHASE3","title":"Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-05","conditions":"Complicated Skin and Soft Tissue Infection","enrollment":802},{"nctId":"NCT03245879","phase":"NA","title":"Antibiotic Stewardship in Small Hospitals","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","startDate":"2013-07","conditions":"Inappropriate Prescribing, Antibiotic Stewardship, Anti-Bacterial Agents","enrollment":30000},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2},{"nctId":"NCT00818766","phase":"NA","title":"Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-03","conditions":"Antibiotic Prophylaxis","enrollment":251},{"nctId":"NCT00770341","phase":"PHASE3","title":"A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"Staphylococcal Infection","enrollment":122}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":5,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":4,"reaction":"RED MAN SYNDROME"},{"count":4,"reaction":"RESPIRATORY FAILURE"},{"count":3,"reaction":"BLOOD CREATININE INCREASED"},{"count":3,"reaction":"HYPOTENSION"},{"count":3,"reaction":"RASH"},{"count":3,"reaction":"RENAL FAILURE"},{"count":2,"reaction":"ACIDOSIS"},{"count":2,"reaction":"ALOPECIA"}],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vancomycin IV","genericName":"Vancomycin IV","companyName":"Debiopharm International SA","companyId":"debiopharm-international-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption. Used for Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA), Bacterial endocarditis, Clostridium difficile-associated diarrhea and colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}